Month: August 2020

33537-99-4, 6-Chloro-1,2,3,4-tetrahydroisoquinoline is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of (/:?)-A/-(3-aminobutyl)-4-(dimethylamino)benzenesulfonamide (0.88 g, 4.0 mmol) in CH3CN (10 ml.) was added 6-chloro-1 ,2,3,4-tetrahydroisoquinoline (1.98 g, 4.0 mmol). The reaction mixture was stirred at ambient temperature overnight. The mixture was concentrated and the residue was purified by column chromatography to provide (/:?)-6-chloro-A/-(4-(4-(dimethylamino)phenylsulfonamido)butan-2-yl)-3,4- dihydroisoquinoline-2(1 /-/)-sulfonamide.

The synthetic route of 33537-99-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; KEZAR LIFE SCIENCES; JOHNSON, Henry; (166 pag.)WO2019/178510; (2019); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

8-Chloro-1,2,3,4-tetrahydroisoquinoline, cas is 75416-50-1, it is a common heterocyclic compound, the tetrahydroisoquinoline compound, its synthesis route is as follows.

General procedure: A mixture of alkylating agent (1equiv), appropriate amine (1.1equiv) K2CO3 (1.1equiv), and KI (catalytic) in DME or CH3CN (50mL) was placed in a round bottomed flask with a stirrer was heated to reflux on a heating plate for 24-28 h. The reaction was monitored by TLC for product formation. After reaction was complete, the resulting crude mixture was directly purified on silica gel by flash chromatography (gradient up to 70% EtOAc in hexanes) to afford the final compounds. The free base where necessary, was converted to the HCl or HBr salt and crystallized out of a mixture of MeOH-Et2O.

With the rapid development of chemical substances, we look forward to future research findings about 75416-50-1

Reference£º
Article; Ofori, Edward; Zhu, Xue Y.; Etukala, Jagan R.; Bricker, Barbara A.; Ablordeppey, Seth Y.; Bioorganic and Medicinal Chemistry; vol. 24; 22; (2016); p. 5730 – 5740;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33537-99-4,6-Chloro-1,2,3,4-tetrahydroisoquinoline,as a common compound, the synthetic route is as follows.

To a stirring solution of 23 (1 mmol, 200mg) in dichloromethane and triethylamine15 (2mmol, 0.3ml) at room temperature was added N-bromosuccinimide (1.1rhmol,200mg). The reaction mixture was stirred at room temperature for 30min. Then2.0 M NaOH aqueous solution was added and the reaction mixture was stirred atrt for another 1 h. The reaction mixture as extracted with DCM. The combinedorganic layer was over MgS04 . The solvent was removed in vacuo. The crude20 product 24 was used in the next step without further purification

#N/A

Reference£º
Patent; MERCK SHARP & DOHME CORP.; MA, Yao; SHIZUKA, Manami; GUZI, Timothy, J.; LIU, Yuan; TIAN, Yuan; LAHUE, Brian, R.; GIBEAU, Craig, R.; SHIPPS, Gerald, W., Jr.; WANG, Yaolin; BOGEN, Stephane, L.; NAIR, Latha, G.; PAN, Weidong; VOSS, Matthew, E.; KIROVA-SNOVER, Margarita; CLAYTON, W. Brent; MCCOY, Mark, A.; WO2013/96150; (2013); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170097-67-3,2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid,as a common compound, the synthetic route is as follows.

To a solution of 2-{[(1 ,1-dimethylethyl)oxy]carbonyl}-1 ,2,3,4-tetrahydro-6- isoquinolinecarboxylic acid (0.1 1 g, 0.4 mmol), HOBt (55 mg, 0.4 mmol), EDCI (77 mg, 0.4 mmol) and triethylamine (140 mul, 1 mmol) in DCM (5 ml.) was added 2-[(4- chlorophenyl)methyl]-4-methyl-1 ,3-thiazol-5-amine hydrochloride (80 mg, 0.33 mmol) and the resulting mixture was stirred at room temperature for 5 days. The organic phase was washed successively with a 1 N solution of hydrochloric acid, with a 1 N solution of sodium hydroxide, dried over Na2SO4, filtered and evaporated under reduced pressure. The residue was purified by flash column chromatography eluting with DCM / EtOAc: 8 / 2 to give the title compound as a yellow oil (25 mg, 15%). LC/MS: m/z 498 (M+H)+, Rt : 3.83 min.

#N/A

Reference£º
Patent; SMITHKLINE BEECHAM CORPORATION; WO2009/150196; (2009); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

5-Bromo-1,2,3,4-tetrahydroisoquinoline, cas is 81237-69-6, it is a common heterocyclic compound, the tetrahydroisoquinoline compound, its synthesis route is as follows.

To a solution of 5-bromo-l,2,3,4-tetrahydroisoquinoline (1.06 g, 10 mmol) in DMF (3 mL) was added zinc cyanide (875 mg, 7.5 mmol) and Pd(P(Ph3)4 (577 mg, 0.5 mmol). The resulting mixture was heated at 100 C and stirred for 15 hrs under N2, then poured into water (30 mL) and extracted with EA (50 mL) twice. The organic layers were combined and washed with water and brine, dried over anhydrous Na2S04 and concentrated in vacuo. The residue was purified by column (eluting with DCM: MeOH =20: 1, v:v) to give l,2,3,4-tetrahydroisoquinoline-5- carbonitrile (400 mg) as a yellow solid.

With the rapid development of chemical substances, we look forward to future research findings about 81237-69-6

Reference£º
Patent; F. HOFFMANN-LA ROCHE AG; HOFFMANN-LA ROCHE INC.; CHENG, Zhanling; WANG, Jianhua; WANG, Min; YANG, Song; (81 pag.)WO2018/83136; (2018); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.42923-77-3,6-Methoxy-1,2,3,4-tetrahydroisoquinoline,as a common compound, the synthetic route is as follows.

To a stirred solution of 6-memoxy-l,2,3,4-tetrahydroisoquinoline (163 mg, 1.0 mmol) in acetonitrile (5.0 ml) is added 2-chloro-(4-cyclobutyl-piperazine)-acetamide (216 mg, 1.0 mmol, 1.0 eq.), K2CO3 (376 mg, 2.0 mmol, 2.0 eq.); and NaI (30 mg). The resulting mixture is stirred at rt overnight. Water (10.0 ml) is added to quench the reaction, and then the acetonitrile is evaporated. The residue is extracted with DCM (10 ml x 3). The extracts are dried over sodium sulfate, and the solvent is removed under reduced pressure to yield a residue that is purified through PTLC (EtOAc/4% TEA) to give the title compound. 1H NMR(300 MHz, CDCl3) delta 6.92 (IH, d), 6.70 (IH, dd), 6.63 (IH, d), 3.77 (3H, s), 3.58~3.68(6H, m), 3.33 (2H, s), 2.86 (2H5 1), 2.74 (2H, t), 2.65(1H, m), 2.27 (4H, m), 1.62-2.06 (6H, m); MS (+VE) m/z 344.2 (M+ +1).

42923-77-3 6-Methoxy-1,2,3,4-tetrahydroisoquinoline 39356, atetrahydroisoquinoline compound, is more and more widely used in various.

Reference£º
Patent; NEUROGEN CORPORATION; WO2007/106349; (2007); A2;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

6-Bromo-1,2,3,4-tetrahydroisoquinoline, cas is 226942-29-6, it is a common heterocyclic compound, the tetrahydroisoquinoline compound, its synthesis route is as follows.

To a mixture of 4-(2-chloro-4-pyrimidinyl)mophiholine (910 mg, 4.56 mmol) and 6-bromo-l,2,3,4- tetrahydroisoquinoline (967 mg, 4.56 mmol) is added anhydrous NMP (12 mL) and the reaction is flushed well with nitrogen. The reaction is then treated with NN- diisopropylethylamine (2.0 mL, 11.45 mmol), capped and placed in a 120 C oil bath for 16 hours. Crude LC/MS seems to indicate complete conversion to the desired product. Removed NuMuRho and Hunig’s base under a stream of nitrogen while heating at 80 C overnight. A yellow solid remained. Took up the solid in EtOAc, heated to dissolve most material in minimum amount of solvent, filtered while hot, allow to cool to RT slowly to give 1.65g (91%) of 4-(2-(6-bromo-3,4-dihydroisoquinolin-2(lH)-yl)pyrimidin-4- yl)morpholine as a pale yellow solid as recrystallized material. LCMS (M+l) = 374.7 and (0235) 376.7.

With the rapid development of chemical substances, we look forward to future research findings about 226942-29-6

Reference£º
Patent; VIIV HEALTHCARE UK (NO.5) LIMITED; BOWSHER, Michael S.; DESKUS, Jeffrey; EASTMAN, Kyle J.; GILLIS, Eric P; FRENNESSON, David B; IWUAGWU, Christiana; NAIDU, B. Narasimhulu; PARCELLA, Kyle E.; PEESE, Kevin M; SAULNIER, Mark G; SIVAPRAKASAM, Prasanna; (220 pag.)WO2018/127801; (2018); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

42923-79-5, 7-Nitro-1,2,3,4-tetrahydroisoquinoline is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step B; To a suspension of the product from Step A (12 g, 58 mmol), and pyridine (23.7 mL, 293 mmol) in anhydrous CH2Cl2 (50 ml) cooled at 0 C. was added in a dropwise manner trifluoroacetic anhydride (12 mL, 87 mmol), and the resulting mixture was stirred at room temperature for 18 h. The reaction mixture was poured onto ice (500 g) and extracted with CH2Cl2 (4¡Á150 mL). The combined CH2Cl2 layers were washed with 1 N HCl (4¡Á100 mL), saturated NaCl (100 mL), dried over Na2SO4, filtered and evaporated in vacuo to give the product (15.92 g, 89%); 1H NMR 500 MHz (CDCl3) delta=3.07 (2H, m), 3.91 and 3.94 (2H, t, J=6.2 Hz), 4.85 and 4.88 (2H, s), 7.36 (1H, dd, J=8.7 and 11.9 Hz), 8.07 (1H, dd, J=2.3 and 8.5 Hz), 8.01-8.08 (2H m).

As the paragraph descriping shows that 42923-79-5 is playing an increasingly important role.

Reference£º
Patent; Butora, Gabor; Goble, Stephen D.; Pastemak, Alexander; Yang, Lihu; Zhou, Changyou; Moyes, Christopher R.; US2008/81803; (2008); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.81237-69-6,5-Bromo-1,2,3,4-tetrahydroisoquinoline,as a common compound, the synthetic route is as follows.

Example 5f 5-bromo-2-(2-(methylsulfonyl)ethyl)-1,2,3,4-tetrahydroisoquinoline A mixture containing 5-bromo-1,2,3,4-tetrahydroisoquinoline (212 mg, 1 mmol) and methylsulfonylethene (106 mg, 1 mmol) in dichloromethane is stirred at 35 C. for 14 hours. The solution is concentrated to afford 5-bromo-2-(2-(methylsulfonyl)ethyl)-1,2,3,4-tetrahydroisoquinoline as a brown oil (LC-MS m/z: 318.1 (M+1)) which is used without further purification in the next step.

81237-69-6 5-Bromo-1,2,3,4-tetrahydroisoquinoline 12823199, atetrahydroisoquinoline compound, is more and more widely used in various.

Reference£º
Patent; Novartis AG; Cheng, Dai; Han, Dong; Zhang, Guobao; Wan, Yongqin; Xie, Yun Feng; Jiang, Jiqing; Gao, Wenqi; Pan, Shifeng; US9216964; (2015); B2;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

6-Methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride, cas is 57196-62-0, it is a common heterocyclic compound, the tetrahydroisoquinoline compound, its synthesis route is as follows.

5.84 3-{4-[4-(6-METHOXY-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YLMETHYL)-BENZYLOXY]-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL}-PIPERIDINE-2,6-DIONE To the CH3CN (10 ml) solution of 3-(4-(4-(bromomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (0.365 g, 0.823 mmol) was added 6-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (0.247 g, 1.235 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.408 ml, 2.470 mmol) at room temperature overnight. Solvent was evaporated and the residue was stirred in CH2Cl2 (100 ml) and washed with sat NaHCO3 (2*30 ml), brine (20 ml) and evaporated to an oil, which was purified by silica gel column (MeOH/CH2Cl2) to give 3-{4-[4-(6-Methoxy-3,4-dihydro-1,1-isoquinolin-2-ylmethyl)-benzyloxy]-1-oxo-1,3-dihydro-isoindol-2-yl}-piperidine-2,6-dione (0.26 g, 60% yield); mp, 169-171 C. HPLC: Waters Symmetry C-18, 3.9*150 mm, 5 mum, 1 mL/min, 240 nm, gradient from 10/90 to 70/30 in 5 min, isocratic at 70/30 for 5 min (CH3CN/0.1% H3PO4), 4.72 min (98.3%). 1H NMR (DMSO-d6) delta 1.90-2.06 (m, 1H, CHH), 2.32-2.46 (m, 1H, CHH), 2.53-2.71 (m, 3H, CH2, CHH), 2.71-2.83 (m, 2H, CH2), 2.83-3.02 (m, 1H, CHH), 3.46 (br. s., 2H, CH2), 3.55-3.81 (m, 5H, CH2, CH3), 4.18-4.50 (m, 2H, CH2), 5.12 (dd, J=5.2, 13.3 Hz, 1H, NCH), 5.23 (br. s., 2H, CH2), 6.58-6.74 (m, 2H, Ar), 6.89 (d, J=9.1 Hz, 1H, Ar), 7.24-7.62 (m, 7H, Ar), 10.98 (br. s., 1H, NH). 13C NMR (DMSO-d6) delta 22.36, 28.94, 31.21, 45.10, 50.12, 51.58, 54.92, 61.51, 69.45, 111.91, 112.93, 114.97, 115.24, 126.73, 127.26, 127.72, 128.82, 129.81, 129.94, 131.81, 133.31, 135.22, 138.28, 153.51, 157.45, 168.01, 169.07, 170.96, 172.83. LC/MS m/e=526. Anal Calcd for C31H31N3O5 (+1.1 H2O): C, 68.27; H, 6.14; N, 7.70. Found: C, 68.08; H, 5.92; N, 7.47.

With the rapid development of chemical substances, we look forward to future research findings about 57196-62-0

Reference£º
Patent; Man, Hon-Wah; Muller, George W.; Ruchelman, Alexander L.; Khalil, Ehab M.; Chen, Roger Shen-Chu; Zhang, Weihong; US2011/196150; (2011); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem